Astrazeneca earnings were $9.4B for the trailing 12 months ending Sep 30, 2025, with 44.9% growth year over year. The latest AZN earnings report on Sep 30, 2025 announced Q3 2025 earnings of $2.5B, up 3.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AZN reported annual earnings of $7.0B, with 18.1% growth.
AZN past earnings growth
How has AZN's earnings growth performed historically?
On AZN's earnings call on Invalid Date, Astrazeneca (NASDAQ: AZN) reported Q3 2025 earnings per share (EPS) of $0.82, up 78.26% year over year. Total AZN earnings for the quarter were $2.53 billion. In the same quarter last year, Astrazeneca's earnings per share (EPS) was $0.46.
As of the last Astrazeneca earnings report, Astrazeneca is currently profitable. Astrazeneca's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $9.40 billion, a 44.71% increase year over year.
What was AZN's earnings growth in the past year?
As of Astrazeneca's earnings date in Invalid Date, Astrazeneca's earnings has grown 44.87% year over year. This is 304.24 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 349.11%. AZN earnings in the past year totalled $9.40 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.